Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
The Centers for Medicare & Medicaid Services (CMS) released its 2021 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System proposed rules. The administration also released an accompanying Executive Order focusing on telehealth and rural healthcare. Learn more.
On July 23, the U.S. Department of Health and Human Services (HHS) Secretary Alex Azar released a renewal of determination to extend the current COVID-19 Public Health Emergency (PHE) by up to another 90 days. The renewal is effective July 25.
On July 31, 2020, the Food and Drug Administration granted accelerated approval to tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, indicated in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. Read more. 
On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Read more.
On July 30, 2020, the Centers for Medicare and Medicaid Services (CMS) announced payment is available to physicians and health care providers to counsel patients at the time of COVID testing about the importance of self-isolation after they are tested and prior to the onset of symptoms. CMS will use existing evaluation and management (E/M) payment codes to reimburse providers who are eligible to bill CMS for counseling services no matter where a test is administered, including doctor’s offices, urgent care clinics, hospitals and community drive-thru or pharmacy testing sites.
ASCO Urges Placing Patient Safety First, Among Other Recommendations One of the nation’s leading cancer organizations says home infusion of anticancer therapy is currently not a safe alternative to outpatient treatment. ASCO—which has recently issued a guide to cancer care delivery during the COVID-19 pandemic and, previously, standards on the safe handling of hazardous drugs—released a position statement that raises concerns about home infusion of anticancer therapy and Centers for Medicare & Medicaid Services (CMS) regulations regarding the practice.
On July 27, 2020, the Senate GOP released its proposal for the next COVID-19 response bill. The bill includes:
ASCO submitted comments to CMS in response to the FY 2021 Hospital Inpatient Prospective Payment System proposed rule. The proposal would establish a new Medicare Severity Diagnosis Related Group (MS-DRG) for procedures involving chimeric antigen receptor T-cell immunotherapies (CAR-T).